Business
Eloxx Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial
Eloxx Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial.
About this update from Eloxx Pharmaceuticals, Inc.
[{"type":"text","content":"\n\n Lead molecule targets genetic nonsense mutation in rare diseases\n Dose escalating study to enroll 36 subjects Data expected in the fourth quarter of 2018 SAN DIEGO and REHOVOT, Israel and BOSTON, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Sevion Therapeutics, Inc. (OTCQB:SVON) and Eloxx Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company developing novel translational read-through inducing drugs (TRIDs) for genetic diseases caused by nonsense mutations, announced today dosing of the first subject in its multiple ascending dose (MAD) Phase 1b clinical trial with its lead candidate, ELX-02.  The double-blind, placebo-controlled, dose-escalating trial will enroll  36  subjects across  4 dose levels, and is designed to evaluate the safety, tolerability and pharmacokinetics of ELX-02 in healthy volunteers (see clinicaltrials.gov, NCT03309605). The trial is being run in Belgium, and data are expected at the end of the fourth quarter 2018. “We are very pleased to continue our clinical development program for ELX-02 and are excited about its potential to treat many genetic diseases caused by nonsense mutations,” said Pedro Huertas, M.D., Ph.D., Chief Medical Officer of Eloxx Pharmaceuticals. “We look forward to continue achieving our key clinical milestones.” ELX-02 is a fifth-generation designer aminoglycoside optimized by medicinal chemistry approaches to act as a translational read-through inducing drug (TRID), enabling the synthesis of full-length proteins. ELX-02 has the potential to treat many rare genetic diseases with high prevalence of nonsense mutations such as cystic fibrosis, cystinosis, mucopolysaccharidosis Type I (MPS I), Rett Syndrome, and Duchenne muscular dystrophy (DMD). About Eloxx PharmaceuticalsEloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. Nonsense mutations are a class of gene defect that result in premature termination of protein synthesis.  As a consequence, patients with a genetic disease caused by nonsense mutations have absent or truncated nonfunctional proteins, accounting for some of the most severe phenotypes in these genetic diseases. Eloxx’s lead product candidate, ELX-02, ...